Citius Pharmaceuticals Inc vs Cassava Sciences Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Cassava Sciences Inc is far larger — about 2.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FLNA | |
|---|---|---|
Market Cap | $20.01M | $47.75M |
Sector | Health | Health |
52-Week High | $1.82 | $4.64 |
52-Week Low | $0.48 | $0.87 |
Enterprise Value | $16.23M | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →